Core Viewpoint - Alcon has released investor discussion materials that emphasize the value of its merger proposal for STAAR stockholders, aiming to strengthen its position in the market [1] Group 1: Merger Proposal - The merger proposal is positioned as beneficial for STAAR stockholders, highlighting potential value creation [1] - Alcon's materials provide detailed insights into the strategic advantages of the merger, including enhanced market presence and operational synergies [1] Group 2: Investor Communication - The release of discussion materials is part of Alcon's broader strategy to engage with investors and clarify the benefits of the proposed merger [1] - Alcon aims to address any concerns from STAAR stockholders regarding the merger, reinforcing its commitment to transparency and shareholder value [1]

Company Overview - STAAR Surgical Company (NASDAQ:STAA) specializes in phakic intraocular lenses (IOLs) with its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The company is based in Lake Forest, California, and is known for its commitment to transparency with investors [1] - STAAR competes in the medical device industry, focusing on innovative vision correction solutions [1] Financial Performance - On October 29, 2025, STAAR reported earnings per share (EPS) of $0.17, slightly below the estimated $0.18 [2] - The company generated revenue of $94.7 million, surpassing the estimated $89.4 million, reflecting strong sales performance [2] Valuation Metrics - The price-to-sales ratio of about 6 indicates that investors are willing to pay $6 for every dollar of sales, showing confidence in the company's revenue potential [3] - The enterprise value to sales ratio is approximately 5.43, reflecting STAAR's valuation relative to its revenue [3] - The enterprise value to operating cash flow ratio is around -42.74, indicating difficulties in generating positive cash flow from operations [3] - STAAR maintains a low debt-to-equity ratio of about 0.12, suggesting a relatively low level of debt compared to its equity [3] Liquidity Position - STAAR's current ratio is approximately 4.94, indicating strong liquidity and the company's ability to cover its short-term liabilities [4] - This strong liquidity position provides a buffer for the company as it continues to focus on its core business of vision correction solutions [4]

Core Viewpoint - Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, has expressed its concerns regarding the adjournment of STAAR's Special Meeting of Stockholders to vote on the proposed sale to Alcon Inc. [1] Group 1 - Yunqi Capital Limited is an investment management firm that advises funds and holds a significant stake in STAAR Surgical Company [1] - The decision to adjourn the Special Meeting of Stockholders was made by STAAR Surgical and Alcon Inc. [1] - The proposed sale to Alcon was initially announced in August [1]

Core Viewpoint - Staar Surgical's largest investor, Broadwood Partners, is initiating a shareholder meeting to remove several directors due to tensions surrounding a proposed takeover [1] Group 1 - Broadwood Partners is the biggest investor in Staar Surgical [1] - The planned shareholder meeting aims to address governance issues by removing certain directors [1] - The tensions arise from a proposed takeover, indicating potential strategic shifts within the company [1]

Core Viewpoint - Broadwood Partners, L.P. intends to call a Special Meeting of STAAR Surgical Company shareholders to remove several directors, indicating potential governance issues within the company [1]. Group 1 - Broadwood Partners owns 27.5% of the outstanding common stock of STAAR Surgical Company [1]. - The notification to the Board of Directors was made yesterday, highlighting the urgency of the situation [1]. - Neal C. Bradsher, the Founder and President of Broadwood, confirmed the intention to call the Special Meeting [1].

Core Viewpoint - Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, opposes the proposed sale of STAAR to Alcon Inc. on the terms announced on August 5, 2025 [1] Group 1 - Yunqi Capital has issued a letter to the Board of Directors of STAAR expressing its opposition to the sale [1] - The opposition is based on the terms of the sale proposed to Alcon Inc. [1]

Core Insights - STAAR Surgical Company, a leader in phakic IOLs, announced preliminary net sales results for Q3 2025, ending September 26, 2025 [1] Company Performance - The announcement of preliminary net sales is made ahead of the quarterly earnings report to provide stockholders with additional insights into the company's performance [1]

Core Viewpoint - Broadwood Partners and its affiliates announced that Institutional Shareholder Services Inc. (ISS) recommended shareholders of STAAR Surgical Company to vote "AGAINST" the proposed acquisition by Alcon Inc. [1] Group 1 - ISS is the third proxy advisory firm to recommend against the proposed merger [1]

Core Points - Broadwood Partners, L.P. and its affiliates have commented on STAAR Surgical Company's recent filing with the SEC regarding a supplement to its definitive proxy statement related to the proposed acquisition by Alcon Inc. [1] Company Summary - Broadwood Partners owns 27.5% of STAAR Surgical Company [1]

Group 1 - Broadwood Partners, L.P. and its affiliates own 27.5% of STAAR Surgical Company's outstanding common shares [1] - Broadwood is urging fellow shareholders to vote against the proposed acquisition of STAAR by Alcon Inc. [1] - The acquisition terms were announced on August 5, 2025 [1]